$Tilray Brands (TLRY.US)$
$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector. TLRY brings is revenues from it's beverages at a growing rate. Earlier in 2024 insiders bought substantial amount of shares on the open market in the...

$FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. The company's platform allows customers to acce...

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech     $Esperion Therapeutics (ESPR.US)$  Esper...

$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector.
TLRY is a lifestyle consumer products company that engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United St...

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech   $Esperion Therapeutics (ESPR.US)$  Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...

$FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO operates a live TV streaming platform for live sports, news, and  entertainment content in the United States and internationally. The  company's platform allows customers to access content through s...

$Esperion Therapeutics (ESPR.US)$ An Investment Now In This Company Should Return 10 X Your Money.
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech   $Esperion Therapeutics (ESPR.US)$  Esperion has the only FDA approved statin al...

$Plug Power (PLUG.US)$ We advise traders to take profit on half your position.
Be careful with PLUG as the company is in need of cash, we see value below $2 so any profit we advise to take it

$Plug Power (PLUG.US)$We lowered our rating to HOLD based on earnings growth is still not enough to gain profits. We believe Trump will win the 2024 election, and that will put pressure on Plug Power.  End of 2025 PLUG is estimated to have a loss of ($-0.57) a share. We expect more dilution will also be needed.
Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has...